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AIM: The mutations in two breast cancer susceptibility genes, BRCA1 and BRCA2,
are frequently associated with familial breast cancer.  In this study, we aimed to inves-
tigate the probable founder mutations of BRCA1 and BRCA2 genes in Iranian breast
cancer patients.
METHODS: The total 400 patients affected with primary breast cancer were included
in this study.  Mutation detection was carried out on the basis of a PCR-based amplifi-
cation, and two founder mutations for BRCA1 (185delAG and 5382insC) and one for
BRCA2 (6174delT) were screened and considered by pedigree analysis.
RESULTS: The positive family histories of breast cancer and other malignancies
were recorded in 27.5% and 52% of patient pedigrees, respectively.  The most frequent
occurrence of breast cancer across four generations revealed to be 50% in the 1st de-
gree in the 3rd generation, 68.8% in the 2nd degree in the 2nd generation, and 59.5% in
the 3rd degree in the 3rd generation.  Only 185delAG mutation in the BRCA1 gene was
found in 2/400 (0.5%) of investigated pedigrees.  There were two sisters of the same
family.  To our interest both sisters carried 185delAG mutation in the BRCA1 gene,
which had a complete penetrance.  However, the mutation was observed with two dif-
ferent organ targeting, at almost an early age of onset (proband: 45 yr, her sister: 30
yr).
CONCLUSION: Considering the importance of genetic counseling and recording, the
adequate information for the pedigrees of cancer patients put forward the principle
approaches in cancer clinics to facilitate early detection for preventing challenges.
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Introduction
Cancer genetics research would provide the complemen-
tary information to the genetics alteration, which finally
could lead to create a database including the adequate data
for the patients affected with breast cancer.  The carriers of
BRCA1 and BRCA2 gene mutations have an increased risk
for developing both breast and ovarian cancers during their
lifetime.  Especially, the BRCA1 defect predisposes to early
onset of the hereditary breast and ovarian cancer.  The num-
bers of mutations in BRCA1 and BRCA2 were estimated to
be 718 and 458, respectively [1].  A large-scale mutation
analysis of these two genes indicated that in many popula-
tions only 30–60% of familial breast cancer are attributable
to BRCA1 and BRCA2 gene mutations [2].
Many examples of founder mutations of BRCA1 and
BRCA2 genes have been reported from different populations
such as the Iceland, Finnish, Dutch, and French families [3-5].
In the east European Ashkenazi population, approximately
40 and 29% of patients with breast  and  ovarian cancer,  res-
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pectively, were diagnosed before the age of 40 yr [6-8].
Three predominant mutations, including 185delAG and
5382insC of BRCA1 gene and 6174delT of BRCA2 gene,
dominantly appeared in the substantial proportion of high-
risk Ashkenazi families [2,9].  These mutations are observed
up to 2.5% of the general Jewish-Ashkenazi population [6].
The 185delAG and Tyr978X alterations were also detected in
non-Ashkenazi Jews [9-11], and rarely in non-Jewish indi-
viduals [12,13].  In addition, the mutation of 8765delAG in
BRCA2 gene was reported from unrelated Yemenite as well
as French-Canadian families, who have exhibited different
BRCA2 haplotypes [14,15].
The present study was planned to investigate the probable
occurrence of 185delAG and 5382insC (BRCA1) and
6174delT (BRCA2) alterations in 400 Iranian breast cancer
patients.
Materials and Methods
Patients
The total 400 primary breast cancer patients, who received
operation at the Day Hospital from 1994 to 2003, were in-
cluded in this study.  The patients included 396 (99%)
women and 4 (1%) men with the mean age of 48.8 ± 11.3 yr,
ranging from 15 to 95 yr.  The tumors were unilateral
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(388/400, 97%), including 208/388 (53.6%) left-sided tumors.
Regarding the histopathological classifications, 332/400
(83%) of tumors were invasive ductal carcinoma, and the
grade of tumors were 26/400 (6.5%), 130/400 (32.5%), and
244/400 (61%) for grades I, II and III, respectively.  The mean
tumor size was 2.97 ± 2.19 cm, ranging from 0.5 to 25 cm.
The axillary lymph node metastasis was detected in 222/400
(55.5%) of the patients.  The tumors exhibited positive
staining for progesterone receptor and estrogen receptor in
228/400 (57%) and 222/400 (55.5%) of patients, respectively.
  
Procedures
The peripheral blood samples were collected from pa-
tients, and the genomic DNA was extracted according the
standard protocol.  Detection of gene mutations was carried
out on the basis of a PCR-based amplification and gel elec-
trophoresis described previously [16].  PCR amplification
was carried out using the oligonucleotide primers listed in
Table 1.  In each PCR reaction, 25 ng of genomic DNA was
added to 20 µl of reaction mixture consisting of 10 × PCR
reaction buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 10 µg/ml
gelatin), 3.25 mM MgCl2, 0.2 mM dNTPs, and 3 U Taq DNA
polymerase (Roche, Penzberg, Germany).  The concentra-
tions of primers used were 2.0 µM for P1 and P3, 0.4 µM for
P2, 0.12 µM for P4, P5, and P6, 0.31 µM for P7 and P9, and
0.24 µM for P8.  Each PCR reaction consisted of an initial 4
min at 94°C, followed by 35 cycles of 94ºC for 30 sec, 57ºC
for 30 sec, and 72ºC for 45 sec, and a final extension step of
10 min at 72°C.  Then, 10 µl of PCR product was mixed with 5
µl of loading dye and subjected to gel electrophoresis in 10%
non-denaturing polyacrylamide (29:1) gel, and finally were
visualized with ethidium bromide staining (Figure 1).
The pedigrees were drawn according to the information
provided by the probands and/or their first-degree relatives
through multiple interviews.
Results
Totally 400 patients affected with primary breast cancer
have been investigated for founder mutations of BRCA1
(185delAG and 5382insC) and BRCA2 (6174delT) genes.  The
family histories positive for breast cancer and other malig-
nancies were recorded in 110/400 (27.5%) and 208/400 (52%)
of patients' pedigrees, respectively.  The most frequent oc-
currence of breast cancer across four generations revealed
to be 20/40 (50%) in the 1st degree in the 3rd generation,
22/32 (68.8%) in the 2nd degree in the 2nd generation, and
22/37 (59.5%) in the 3rd degree in the 3rd generation (Table
2).
The pedigree of family A (Figure 2A) included  the proband
                     Table 1: Oligonucleotide sequences of primers used for detection of three founder mutations of BRCA1 and BRCA2
                        genes
Oligonucleotide primer sequencea Size of amplified segment
BRCA1 185delAG
Common forward (P1) 5’-ggttggcagcaatatgtgaa-3’
Wild-type reverse (P2) 5’-gctgacttaccagatgggactctc-3’ 335 bp
Mutant reverse (P3) 5’-cccaaattaatacactcttgtcgtgacttaccagatgggacagta-3’ 354 bp
BRCA1 5382insC
Common reverse (P4) 5’-gacgggaatccaaattacacag-3’
Wild-type forward (P5) 5’-aaagcgagcaagagaatcgca-3’ 271 bp
Mutant forward (P6) 5’-aatcgaagaaaccaccaaagtccttagcgagcaagagaatcacc-3’ 295 bp
BRCA2 6174delT
Common reverse (P7) 5’-agctggtctgaatgttcgttact-3’
Wild-type forward (P8) 5’-gtgggatttttagcacagctagt-3’ 151 bp
Mutant forward (P9) 5’-cagtctcatctgcaaatacttcagggatttttagcacagcatgg-3’ 171 bp
                                               aThe sequences of primers were previously reported by Chan et al. [16].
Figure 1: Gel electrophoresis analysis
of the PCR products of genomic DNA
isolated from primary breast cancer
patients.  The sequences of the oli-
gonucleotide primers P1~P9 used for
PCR reactions are listed in Table 1.  The
presence of the band with a size of 354
bp indicates the BRCA1 gene heterozy-
gosity resulting from 185delAG muta-
tion.  Lane 1, DNA size marker.  Lanes 2-
12, examples of the PCR results from 11
breast cancer patients.
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                      Table 2: Distribution of breast cancer among relatives across different generations and relative degrees
1st Generation 2nd Generation 3rd Generation 4th Generation Total
1st Degree - 17 20 3 40
2nd Degree 3 22 3 4 32
3rd Degree 7 7 22 1 37
4th Degree 0 0 1 0 1
Total 10 46 46 46 110        
                       *Data are presented as numbers of involved relatives.  The bold outcomes are considered as most frequent
                            involvement.
Figure 2: The pedigrees of two breast cancer patients with the 185delAG mutation in BRCA1 gene. (A) The members of family A included: II/1,
affected with gastric cancer at age of 60 yr; II/5, affected with unknown cancer; III/2, affected with brain tumor at age of 35 yr and carried 185delAG
mutation but without any mutation in exons 4-9 of p53 gene; III/3, affected with primary breast cancer at age of 46 yr and carried 185delAG muta-
tion.  The proband is indicated by the arrow.  (B) The members of family B included: III/5, affected with liver cancer at age of 35 yr and deceased at
the same age; IV/2: affected with breast cancer at age of 45 yr; IV/8, having a benign breast tumor at age of 16 yr; IV/9, affected with breast cancer
at age of 44 yr and carried 185delAG mutation; V/1, affected with breast cancer at age of 30 yr and deceased at age of 35 yr; V/2: affected with colon
cancer at age of 56 yr and deceased at age of 69 yr.  Arrow is indicative of proband.
(III/3) afflicted with primary breast cancer at age of 46 yr, and
her sister (III/2) manifested the brain tumor diagnosed as
meningioma (meningiotheliomatous type) at age of 35 yr.
Both of sisters carried the 185delAG mutation in BRCA1
gene.  The proband’s sister had no mutation in exons 4-9 of
p53 gene (our unpublished data).  An affected uncle (II/1),
who manifested gastric cancer at age of 60 yr and had de-
ceased at 65 yr, and the mother-in-law of proband’s sister
(II/5) with an unknown cancer were also included in this
pedigree.
The pedigree of family B (Figure 2B) involved a breast
cancer proband (IV/2) at age of 45 yr who carried the
185delAG mutation in BRCA1 gene.  The relatives affected
with cancers included an unrelated individual (III/5) who was
diagnosed for liver tumor and had deceased at 35 years old.
The proband’s cousin (IV/8) was diagnosed to have the be-
nign breast tumor at age of 16 yr.  Two more family members
included a breast cancer patient (V/1) aged at 30 yr and de-
ceased at 35 yr and one affected relative (V/2) with colon
cancer aged at 56 yr and deceased 13 yr later.  Both of these
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patients were the third cousins from the paternal line of the
breast cancer proband of family B (Figure 2B).
In our 400 patients, we did not find the other two muta-
tions, i.e. 5382insC in BRCA1 gene and 6174delT in BRCA2
gene.
Discussion
The frequencies of BRCA1 and BRCA2 gene mutations
varied greatly in the large scale of breast cancer pedigrees
of different countries and populations, which included 21%
and 9% in Britain, 24% and 18% in France, 40% and 16% in
Canada, and 39% and 25% in the USA, respectively, and in
either genes 35% represented in the families of Sweden and
Hungary [4].  Neither the 1100delAT (BRCA1) nor the
8765delAG (BRCA2) mutation was detected in the high-risk
Jewish, non-Ashkenazi individuals of Yemenite and North
African origin [17].  Whereas, the 8765delAG (BRCA2) muta-
tion occurred at a high frequency in Sardinian high-risk
families [18].  The 5382insC mutation in BRCA1 was specific
for Ashkenazi and Russian populations, and could also
serve as a founder mutation in the Turkish population, sug-
gesting a certain level of admixture between Jewish, Russian,
and Turkish individuals in spite of religious and cultural
barriers separating these diverse populations [19].  Out of 24
familial breast cancer patients studied from two different
geographic regions/populations of India, two sisters from a
family (12.5%) out of eight families from Goa with Portugue-
se colonial origin showed the presence of founder Ashke-
nazi Jewish BRCA1 mutation (185delAG) [20].  Regarding the
mutation data of Iranian population, a novel deletion
c.4415_4418delAGAA, an insertion c.6033_6034insGT, one
intronic variation g.5075–53C>T, a deletion/insertion
g.81_389del9ins29 in the 3’-untranslated region of BRCA1
and a previously described insertion c.6033_6034insGT have
been reported [21-24].
In this study, the 185delAG mutation in BRCA1 gene was
found in 0.5% of investigated pedigrees and in 0.75% of pa-
tients.  Among them, the family A showed 185delAG muta-
tion in two members, including the proband (III/3) and her
sister (III/2).  Although they both carried the same genetic
alteration and had complete penetrance, but the mutation of
BRCA1 gene was associated with two different organ tar-
geting (i.e. breast vs. brain cancer) and neoplastic behaviors
(i.e. the malignant vs. benign natures) at almost an early age
of onset (proband: 45 yr, sister: 30 yr).  However, there were
important key elements in families A and B, which could lead
to a plan to address the challenges of preventive genetics
and to consider an appropriate management for the healthy
relatives as following.  The age of onset for breast cancer,
either in the probands or in the proband’s relatives of both
families A and B, was found to be within the same range (i.e.
44-46 yr) except the 3rd cousin of proband (V/1) in family B
who was affected at age of 30 and deceased at age of 35.  To
draw the attention towards the recorded family history of
breast cancer and other malignancies, even the unrelated
individuals in the same pedigree, could provide a great im-
pact on the future management for their offspring.  In this
regard, two individuals (II/1 and II/5) in the family B could be
exemplified.  If they carried a mutation, the complexity of
genetic alterations and the outcome for the offspring in the
generation IV and V could be early diagnosed and predicted.
Due to the lack of any report on the founder mutations in
BRCA1 and BRCA2 from Iran, the result of this study has
provided the preliminary information to understand the level
of involvement of BRCA1 and BRCA2 mutations in the breast
cancer occurrence of Iranian population.  The screening on
other mutations, such as c.4415_4418delAGAA,
c.6033_6034insGT, g.5075–53C>T, and g.81_389del9ins29, in
BRCA1 gene is ongoing to confirm the result.  In addition,
the comprehensive sequencing of BRCA1 and BRCA2 and
their haplotype analyses will also be performed to determine
whether the founder mutations of these genes are unique to
Iranian population.  In conclusion, our observation of the
185delAG mutation of BRCA1 gene in three investigated
family members could suggest the clinician to provide a
preventive genetic test of the BRCA1 defect in the healthy
and affected family members, either affected with breast
cancer or other types of cancer, as early as possible.
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